KAYTUS
14.5.2024 09:01:37 CEST | Business Wire | Press release
KAYTUS, a leading IT infrastructure provider, has unveiled its latest upgrade, the K24V2 multi-node server, at ISC High Performance 2024. This server supports four dual-socket nodes within a compact 2U form factor, featuring a total of eight cutting-edge Intel/AMD processors. The K24V2 incorporates advanced cooling technologies optimized for extreme computing density, offering both cold plate liquid cooling and air cooling configurations. Notably, the liquid-cooling K24V2 cools components that account for more than 80% of the total power consumption, while the air-cooled variant supports CPU cooling with a TDP of up to 400W. With its emphasis on high performance, energy efficiency, and exceptional reliability, the K24V2 is tailored for demanding tasks such as modeling, simulation, and other performance-intensive applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513994533/en/
K24V2 Multi-Node Server (Photo: Business Wire)
Achieving Four Times Computing Density and Higher Performance
The K24V2 server enables support for four dual-socket nodes within a 2U form factor, allowing for independent operations between nodes. Each node is compatible with two 5th Gen Intel® Xeon® processors or the latest 4th Gen AMD EPYC™ processors. It supports memory configurations up to 5600MT/s, and each node can accommodate various networking extensions such as InfiniBand, Omni-Path Architecture, and RoCE, meeting the networking requirements for HPC clusters.
Leading Cooling Solutions for Enhanced Performance and Efficiency
The liquid-cooled configuration of the K24V2 incorporates an integrated cold plate design that covers key components including the CPU, memory, and VR (Voltage Regulator). Components accounting for more than 80% of total power consumption are liquid cooled, offering efficient cooling while balancing investment control and power usage for heat dissipation. The cold plate supports various liquid-cooling connectors like SCG 03 and DAG 03, ensuring compatibility with different liquid-cooling cabinets used in data centers. The K24V2 is capable of supporting high-temperature inlet cooling liquids of up to 45°C, with the primary loop capable of drawing intake from a natural draft cooling tower. Furthermore, engineered to operate efficiently at an industry-leading ambient temperature of 45°C, this system significantly reduces energy consumption in data center operations.
The air-cooled version of the K24V2 maximizes heat dissipation performance through a high air intake design and a customized heat sink. This variant supports high-density deployments with CPUs of up to 400W TDP, delivering ultra-high performance and dense computing power tailored for air-cooled data centers.
Ensuring Security and Reliability, Streamlining Operations and Maintenance
Aside from delivering industry-leading performance per watt, the K24V2 is highly secure and reliable. The four nodes share titanium power supply units (PSUs), and the entire system supports N+N or 3+1 redundancy configurations. The liquid-cooled version features an integrated cold plate design and undergoes rigorous inspection processes before leaving the factory, including a nitrogen pressure test to effectively prevent leaks. Notably, the liquid-cooled version can identify leaking nodes in real-time, automatically cutting off node power to ensure the safety of equipment and data assets.
The K24V2 enhances user experience by offering convenient operation and maintenance features. The four nodes support hot-swappable maintenance and feature a "button"-style node switching on the front panel. This simplifies the connection of maintenance equipment for unified operations and maintenance, reduces work in the backend hot air duct, and improves overall user-friendliness.
To learn more about the new KAYTUS K24V2 Multi-Node Server, please visit our website.
About KAYTUS
KAYTUS is a prominent provider of IT infrastructure solutions, delivering a diverse range of innovative, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513994533/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
